恶性胸膜间皮瘤诊断及治疗最新进展
Recent Progress in Diagnosis and Treatment of Malignant Pleural Mesothelioma
DOI: 10.12677/acm.2024.1472069, PDF,   
作者: 沈宇杰, 沈 枭, 蒋一胜, 周徐雷：绍兴文理学院医学院，浙江 绍兴；喻光懋*：绍兴市人民医院胸外科，浙江 绍兴
关键词: 恶性胸膜间皮瘤；手术治疗；化疗；放疗；免疫治疗；Malignant Pleural Mesothelioma； Surgical Treatment； Chemotherapy； Radiotherapy； Immunotherapy
摘要: 恶性胸膜间皮瘤(Malignant pleural mesothelioma, MPM)是一种少见的恶性肿瘤，主要是由于石棉暴露。恶性胸膜间皮瘤诊断和治疗具有挑战性。通过X线、CT、MRI、PET/CT、胸腔穿刺活检及血清学等检查，可正确诊断恶性胸膜间皮瘤。对于无法手术的患者培美曲塞联合铂类药物化疗是主要的治疗方法。本文主要阐释恶性胸膜间皮瘤的诊断及治疗最新进展。
Abstract: Malignant pleural mesothelioma (MPM) is a rare malignant tumor, mainly due to the asbestos exposure. Diagnosis and treatment of malignant pleural mesothelioma can be challenging. Malignant pleural mesothelioma can be correctly diagnosed by X-ray, CT, MRI, PET/CT, thoracic puncture biopsy and serology. The combination of pemetrexed and platinum-based chemotherapy is the main therapy for patients with inoperable cancer. In this paper, we summarize the recent advances in the diagnosis and therapy of malignant pleural mesothelioma.
文章引用：沈宇杰, 沈枭, 蒋一胜, 周徐雷, 喻光懋. 恶性胸膜间皮瘤诊断及治疗最新进展[J]. 临床医学进展, 2024, 14(7): 696-702. https://doi.org/10.12677/acm.2024.1472069

参考文献

[1] Perera, N.D. and Mansfield, A.S. (2022) The Evolving Therapeutic Landscape for Malignant Pleural Mesothelioma. Current Oncology Reports, 24, 1413-1423. [Google Scholar] [CrossRef] [PubMed]
[2] Nakajima, E.C., Vellanki, P.J., Larkins, E., Chatterjee, S., Mishra-Kalyani, P.S., Bi, Y., Qosa, H., Liu, J., Zhao, H., Biable, M., Hotaki, L.T., Shen, Y.L., Pazdur, R., Beaver, J.A., Singh, H. and Donoghue, M. (2022) FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma. Clinical Cancer Research, 28, 446-451. [Google Scholar] [CrossRef] 
[3] Sun, H.H., Vaynblat, A. and Pass, H.I. (2017) Diagnosis and Prognosis-Review of Biomarkers for Mesothelioma. Annals of Translational Medicine, 5, Article 244. [Google Scholar] [CrossRef] [PubMed]
[4] Schillebeeckx, E., van Meerbeeck, J.P. and Lamote, K. (2021) Clinical Utility of Diagnostic Biomarkers in Malignant Pleural Mesothelioma: A Systematic Review and Meta-Analysis. European Respiratory Review, 30, Article 210057. [Google Scholar] [CrossRef] [PubMed]
[5] Cavallari, I., Urso, L., Sharova, E., Pasello, G. and Ciminale, V. (2019) Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives. Frontiers in Oncology, 9, Article 740. [Google Scholar] [CrossRef] [PubMed]
[6] Pass, H.I., Alimi, M., Carbone, M., Yang, H. and Goparaju, C.M. Mesothelioma Biomarkers: Discovery in Search of Validation. Thoracic Surgery Clinics, 30, 395-423.[CrossRef] [PubMed]
[7] 杨晓川, 张强. 影像学检查在恶性胸膜间皮瘤中的应用[J]. 影像研究与医学应用, 2019, 3(1): 1-3.
[8] Gill, R.R., Patz, S., Muradyan, I. and Seethamraju, R.T. (20150 Novel MR Imaging Applications for Pleural Evaluation. Magnetic Resonance Imaging Clinics of North America, 23, 179-195.[CrossRef] [PubMed]
[9] Dubreuil, J., Giammarile, F., Rousset, P., Rubello, D., Bakrin, N., Passot, G., Isaac, S., Glehen, O. and Skanjeti, A. (2017) The Role of 18F-FDG-PET/Cect in Peritoneal Mesothelioma. Nuclear Medicine Communications, 38, 312-318. [Google Scholar] [CrossRef] 
[10] Barbieri, P.G., Consonni, D. and Schneider, M. (2022) Accuracy of Pleural Biopsy for the Diagnosis of Histologic Subtype of Malignant Pleural Mesothelioma: Necropsy-Based Study of 134 Cases. Tumori Journal, 108, 26-32. [Google Scholar] [CrossRef] [PubMed]
[11] Butchart, E.G., Ashcroft, T., Barnsley, W.C. and Holden, M.P. (1976) Pleuropneumonectomy in the Management of Diffuse Malignant Mesothelioma of the Pleura. Experience with 29 Patients. Thorax, 31, 15-24. [Google Scholar] [CrossRef] [PubMed]
[12] Sugarbaker, D.J., Strauss, G.M., Lynch, T.J., Richards, W., Mentzer, S.J., Lee, T.H., Corson, J.M. and Antman, K.H. (1993) Node Status Has Prognostic Significance in the Multimodality Therapy of Diffuse, Malignant Mesothelioma. Journal of Clinical Oncology, 11, 1172-1178. [Google Scholar] [CrossRef] 
[13] Rusch, V.W., Chansky, K., Kindler, H.L., Nowak, A.K., Pass, H.I., Rice, D.C., Shemanski, L., Galateau-Sallé, F., Mccaughan, B.C., Nakano, T., Ruffini, E., van Meerbeeck, J.P. and Yoshimura, M. (2016) The IASLC Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions. The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma. Journal of Thoracic Oncology, 11, 2112-2119.
[14] 丁婧, 林桐榆. 恶性胸膜间皮瘤治疗展望[J]. 肿瘤预防与治疗, 2023, 36(4): 271-279.
[15] Yorke, E.D., Jackson, A., Kuo, L.C., Ojo, A., Panchoo, K., Adusumilli, P., Zauderer, M.G., Rusch, V.W., Shepherd, A. and Rimner, A. (2017) Heart Dosimetry Is Correlated with Risk of Radiation Pneumonitis after Lung-Sparing Hemithoracic Pleural Intensity Modulated Radiation Therapy for Malignant Pleural Mesothelioma. International Journal of Radiation Oncology, Biology, Physics, 99, 61-69. [Google Scholar] [CrossRef] [PubMed]
[16] Taioli, E., Wolf, A.S. and Flores, R.M. (2015) Meta-Analysis of Survival after Pleurectomy Decortication versus Extrapleural Pneumonectomy in Mesothelioma. The Annals of Thoracic Surgery, 99, 472-480. [Google Scholar] [CrossRef] [PubMed]
[17] Popat, S., Baas, P., Faivre-Finn, C., Girard, N., Nicholson, A.G., Nowak, A.K., Opitz, I., Scherpereel, A. and Reck, M. (2022) Malignant Pleural Mesothelioma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 33, 129-142. [Google Scholar] [CrossRef] [PubMed]
[18] Zalcman, G., Mazieres, J., Margery, J., Greillier, L., Audigier-Valette, C., Moro-Sibilot, D., Molinier, O., Corre, R., Monnet, I., Gounant, V., Rivière, F., Janicot, H., Gervais, R., Locher, C., Milleron, B., Tran, Q., Lebitasy, M.P., Morin, F., Creveuil, C., Parienti, J.J. and Scherpereel, A. (2016) French Cooperative Thoracic Intergroup (IFCT). Bevacizumab for Newly Diagnosed Pleural Mesothelioma in The Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A Randomised, Controlled, Open-Label, Phase 3 Trial. The Lancet, 387, 1405-1414. [Google Scholar] [CrossRef] 
[19] 唐善卫, 唐桂旺, 束余声. 恶性胸膜间皮瘤治疗的研究进展[J]. 癌症进展, 2019, 17(11): 1245-1250.
[20] Stahel, R.A., Riesterer, O., Xyrafas, A., Opitz, I., Beyeler, M., Ochsenbein, A., Früh, M., Cathomas, R., Nackaerts, K., Peters, S., Mamot, C., Zippelius, A., Mordasini, C., Caspar, C.B., Eckhardt, K., Schmid, R.A., Aebersold, D.M., Gautschi, O., Nagel, W., Töpfer, M., Krayenbuehl, J., Ribi, K., Ciernik, I.F. and Weder, W. (2015) Neoadjuvant Chemotherapy and Extrapleural Pneumonectomy of Malignant Pleural Mesothelioma with or Without Hemithoracic Radiotherapy (SAKK 17/04): A Randomized, International, Multicentre Phase 2 Trial. The Lancet Oncology, 16, 1651-1658. [Google Scholar] [CrossRef] 
[21] Khan, A.M.H., Anwer, S.H., Sayed, S., Mansha, M.A., Kamran, Y.B., Khursheed, A., Haroon, F., Soomro, N.H., Idrees, R. and Abbasi, A.N. (2024) Comprehensive Clinical Overview of Malignant Pleural Mesothelioma. Respiratory Medicine, 222, Article 107511. [Google Scholar] [CrossRef] [PubMed]
[22] Barsky A.R., Cengel K.A., Katz S.I., Sterman D.H. and Simone Ⅱ, C.B. (2019) First-Ever Abscopal Effect after Palliative Radiotherapy and Immuno-Gene Therapy for Malignant Pleural Mesothelioma. Cureus, 11, E4102. [Google Scholar] [CrossRef] [PubMed]
[23] Rimner, A., Hu, C., Zauderer, M., et al. (2020) A Phase III Randomized Trial of Pleurectomy/Decortication Plus Chemotherapy with or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma (MPM) (NRG-LU006). International Journal of Radiation Oncology, Biology, Physics, 108, E928-E929. [Google Scholar] [CrossRef] 
[24] Bayman, N., Appel, W., Ashcroft, L., Baldwin, D.R., Bates, A., Darlison, L., Edwards, J.G., Ezhil, V., Gilligan, D., Hatton, M., Jegannathen, A., Mansy, T., Peake, M.D., Pemberton, L., Rintoul, R.C., Snee, M., Ryder, W.D., Taylor, P. and Faivre-Finn, C. (2019) Prophylactic Irradiation of Tracts in Patients with Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial. Journal of Clinical Oncology, 37, 1200-1208. [Google Scholar] [CrossRef] 
[25] Borea, F., Franczak, M.A., Garcia, M., Perrino, M., Cordua, N., Smolenski, R.T., Peters, G.J., Dziadziuszko, R., Santoro, A., Zucali, P.A. and Giovannetti, E. (2023) Target Therapy in Malignant Pleural Mesothelioma: Hope or Mirage? International Journal of Molecular Sciences, 24, Article 9165. [Google Scholar] [CrossRef] [PubMed]
[26] Nowak, A.K., Brosseau, S., Cook, A. and Zalcman, G. (2020) Antiangiogeneic Strategies in Mesothelioma. Frontiers in Oncology, 10, Article 126. [Google Scholar] [CrossRef] [PubMed]
[27] Tsao, A.S., Harun, N., Lee, J.J., Heymach, J., Pisters, K., Hong, W.K., Fujimoto, J. and Wistuba, I. (2014) Phase I Trial of Cisplatin, Pemetrexed, and Imatinib Mesylate in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma. Clinical Lung Cancer, 15, 197-201. [Google Scholar] [CrossRef] [PubMed]
[28] Onen, H.I., Yilmaz, A., Alp, E., Celik, A., Demiroz, S.M., Konac, E., Kurul, I.C. and Menevse, E.S. (2015) EF24 and RAD001 Potentiates the Anticancer Effect of Platinum-Based Agents in Human Malignant Pleural Mesothelioma (MSTO-211H) Cells and Protects Nonmalignant Mesothelial (MET-5A) Cells. Human & Experimental Toxicology, 34, 117-126. [Google Scholar] [CrossRef] [PubMed]
[29] Baas, P., Scherpereel, A., Nowak, A.K., Fujimoto, N., Peters, S., Tsao, A.S., Mansfield, A.S., Popat, S., Jahan, T., Antonia, S., Oulkhouir, Y., Bautista, Y., Cornelissen, R., Greillier, L., Grossi, F., Kowalski, D., Rodríguez-Cid, J., Aanur, P., Oukessou, A., Baudelet, C. and Zalcman, G. (2021) First-Line Nivolumab Plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma (Checkmate 743): A Multicentre, Randomized, Open-Label, Phase 3 Trial. The Lancet, 397, 375-386. [Google Scholar] [CrossRef] 
[30] Sterman, D.H., Alley, E., Stevenson, J.P., Friedberg, J., Metzger, S., Recio, A., Moon, E.K., Haas, A.R., Vachani, A., Katz, S.I., Sun, J., Heitjan, D.F., Hwang, W.T., Litzky, L., Yearley, J.H., Tan, K.S., Papasavvas, E., Kennedy, P., Montaner, L.J., Cengel, K.A., Simone Ⅱ, C.B., Culligan, M., Langer, C.J. and Albelda, S.M. (2016) Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNΑ Combined with Chemotherapy. Clinical Cancer Research, 22, 3791-3800. [Google Scholar] [CrossRef] 

为你推荐